Nagoya-Based Taiyo Calls Off Price Listing For 12 Drugs
This article was originally published in PharmAsia News
Executive Summary
Taiyo Pharmaceutical has decided not to seek price listing for 12 generic drugs as a measure to tighten its quality control system and restore public trust after a drug quality control scandal led to a halt in production